Log In
Print
BCIQ
Print
Print this Print this
 

Ondansetron lingual spray (Zensana) (BA-029)

  Manage Alerts
Collapse Summary General Information
Company Suda Ltd.
DescriptionOndansetron lingual spray
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy- and radiation-induced and post-operative nausea and vomiting (PONV); Prevent nausea and vomiting associated with chemotherapy and radiotherapy as well as post-operative induced nausea and vomiting; Treat chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation

Partner

Onxeo S.A.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.8M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today